乌司奴单抗在抗TNF治疗失败的克罗恩病患者中疗效优于维得利珠单抗
这项前瞻性荷兰注册研究比较了抗TNF治疗失败后换用乌司奴单抗或维得利珠单抗的克罗恩病患者,经过52周治疗,乌司奴单抗组在无激素临床缓解、生化缓解及联合缓解方面均优于维得利珠单抗组,而安全性结局两组相当。
要点
- 抗TNF失败的CD患者换用乌司奴单抗,52周无激素临床缓解率显著优于维得利珠单抗(OR 2.58)。
- 乌司奴单抗组生化缓解和联合缓解也显著更优,安全性结局与维得利珠单抗相当。
- 倾向性评分匹配敏感性分析结果与主要分析一致,支持结论稳健。
核心结论
- 在抗TNF治疗失败的CD患者中,乌司奴单抗在52周时的疗效结局优于维得利珠单抗,而安全性结局相当。
研究设计与样本
- 前瞻性观察性荷兰克罗恩病和结肠炎倡议注册研究,纳入抗TNF治疗失败后开始维得利珠单抗(128例)或乌司奴单抗(85例)作为二线生物制剂的患者。
- 采用多因素逻辑回归和倾向性评分匹配校正混杂因素和选择偏倚,比较治疗52周后的结局。
主要发现
- 校正混杂因素后,乌司奴单抗组达到无激素临床缓解(HBI≤4)的几率更高(OR 2.58,95%CI 1.36-4.90,P=0.004)。
- 乌司奴单抗组生化缓解(CRP≤5 mg/L且粪钙卫蛋白≤250 µg/g)几率更高(OR 2.34,95%CI 1.10-4.96,P=0.027)。
- 乌司奴单抗组联合无激素临床和生化缓解几率更高(OR 2.74,95%CI 1.23-6.09,P=0.014)。
- 安全性结局两组相当:感染(OR 1.26,95%CI 0.63-2.54,P=0.517)、不良事件(OR 1.33,95%CI 0.62-2.81,P=0.464)、住院(OR 0.67,95%CI 0.32-1.39,P=0.282)。
- 倾向性评分匹配队列的敏感性分析显示可比的结果。
关键数值与推荐
- 无激素临床缓解定义为Harvey Bradshaw指数≤4。
- 生化缓解定义为C反应蛋白≤5 mg/L且粪钙卫蛋白≤250 µg/g。
- 联合缓解定义为同时达到无激素临床缓解和生化缓解。
临床怎么用
- 对于抗TNF治疗失败的CD患者,乌司奴单抗可作为优先考虑的二线生物制剂选择。
- 维得利珠单抗仍是可选方案,但需告知患者其疗效可能低于乌司奴单抗。
局限性
- 观察性注册研究,尽管采用多因素回归和倾向性评分匹配校正混杂,仍可能存在未测量混杂。
- 样本量有限(维得利珠单抗128例,乌司奴单抗85例),结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both vedolizumab and ustekinumab can be considered for the treatment of Crohn's disease (CD) when anti-TNF treatment fails. However, head-to-head trials are currently not available or planned. AIM: To compare vedolizumab and ustekinumab in Crohn´s disease patients in a prospective registry specifically developed for comparative studies with correction for confounders. METHODS: Crohn´s disease patients, who failed anti-TNF treatment and started vedolizumab or ustekinumab in standard care as second-line biological, were identified in the observational prospective Dutch Initiative on Crohn and Colitis Registry. Corticosteroid-free clinical remission (Harvey Bradshaw Index ≤4), biochemical remission (C-reactive protein ≤5 mg/L and fecal calprotectin ≤250 µg/g), combined corticosteroid-free clinical and biochemical remission, and safety outcomes were compared after 52 weeks of treatment. To adjust for confounding and selection bias, we used multiple logistic regression and propensity score matching. RESULTS: In total, 128 vedolizumab- and 85 ustekinumab-treated patients fulfilled the inclusion criteria. After adjusting for confounders, ustekinumab-treated patients were more likely to achieve corticosteroid-free clinical remission (odds ratio [OR]: 2.58, 95% CI: 1.36-4.90, P = 0.004), biochemical remission (OR: 2.34, 95% CI: 1.10-4.96, P = 0.027), and combined corticosteroid-free clinical and biochemical remission (OR: 2.74, 95% CI: 1.23-6.09, P = 0.014), while safety outcomes (infections: OR: 1.26, 95% CI: 0.63-2.54, P = 0.517; adverse events: OR: 1.33, 95% CI: 0.62-2.81, P = 0.464; hospitalisations: OR: 0.67, 95% CI: 0.32-1.39, P = 0.282) were comparable between the two groups. The propensity score matched cohort with sensitivity analyses showed comparable results. CONCLUSIONS: Ustekinumab was associated with superior effectiveness outcomes when compared to vedolizumab, while safety outcomes were comparable after 52 weeks of treatment in CD patients who have failed anti-TNF treatment.
引用
- Biemans VBC, van der Woude CJ, Dijkstra G, et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther. 2020. PMID: 32441396. doi:10.1111/apt.15745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。